New drug combination effective for patients with advanced ovarian cancer
A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.
Materials provided by Yale University. Note: Content may be edited for style and length.
Source link aaaaa